Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes



: Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P, ACCOAST Investigators

Publisher: MASSACHUSETTS MEDICAL SOC

: 2013

: New England Journal of Medicine

: NEW ENGLAND JOURNAL OF MEDICINE

: NEW ENGL J MED

: 11

: 369

: 11

: 999

: 1010

: 12

: 0028-4793

DOI: https://doi.org/10.1056/NEJMoa1308075


ConclusionsAmong patients with NSTE acute coronary syndromes who were scheduled to undergo catheterization, pretreatment with prasugrel did not reduce the rate of major ischemic events up to 30 days but increased the rate of major bleeding complications. (Funded by Daiichi Sankyo and Eli Lilly; ACCOAST ClinicalTrials.gov number, NCT01015287.)



Last updated on 2024-26-11 at 12:34